Side effects of lower dose compounded semaglutide paired with a behavioral management program: A real-world retrospective study
- Design
- Retrospective cohort
- Drugs
- Semaglutide
- Assessment
- Facts extracted automatically · reviewed by Carrie Schluter, Nov 5, 2026 · added Nov 6, 2026
This study was added automatically, and its details were extracted by machine rather than read off the paper by a person. Carrie Schluter has reviewed the record, but that review did not re-extract those details, so the collection still publishes no population match, weight-loss explanation, study tier, findings, population or funding details for it: a check of automatically extracted details found too many errors to show them as fact. The abstract below is the source as retrieved. This item has not been peer reviewed.
01Source
The source, as retrieved
Abstract
ObjectiveEvaluate differences in side effects between a low and standard dose compounded semaglutide paired with a behavioral companion in the first 16 weeks of treatment using a real-world, retrospective cohort. MethodsSide effects were compared between the low dose protocol (Noom Microdose GLP-1 Rx Program; NMGP, up to 0.6mg/weekly compounded semaglutide) and Nooms standard dose of compounded semaglutide (Noom GLP-1 Rx Program; NGP, up to 1.2mg/weekly). Users were propensity score matched on side effect rate in the first 8 weeks when dosing protocols were identical, and longitudinal side effect trajectories were compared via logistic regression. Analyses were conducted on a second cohort with additional matched baseline characteristics. ResultsThe full sample included 7,682 NGP and 2,877 NMGP users. NMGP users had 34% lower and 29% lower relative odds of reporting GI side effects (p=0.001) and any side effects (p=0.001) by week 16, respectively (n=2,481 per group). Results of the second cohort demonstrated 38% lower odds of any side effect by week 16 among NMGP users (n=958 per group, p=0.019). ConclusionsLower doses of compounded semaglutide alongside a behavioral companion are associated with fewer side effects in the first 16 weeks compared to a higher dose program.
Where this record came from
| Source | Retrieved | Identifier |
|---|---|---|
| medrxiv:medrxiv | Sep 20, 2026 | 10.64898/2026.09.08.26362532 first ingestion |
| owner-review | Nov 6, 2026 | reviewed_by set to Carrie Schluter (2026-11-05) on the owner's own confirmation. The assessment is unchanged and still the auto-classifier's, so its extracted values stay withheld under the 2026-10-18 decision. |
| reextract | Nov 6, 2026 | dose: '0.6mg/week' -> '0.6 mg/weekly'. Q-043: manufacturer and drug_details.dose re-extracted by auto-classifier-v1.2. manufacturer no longer reads companies named only in the authors' conflicts statement (IN-062) and refuses a multi-company roster; dose is tied to the GLP-1 agent by name, never reads a concentration, and records a multi-dose design whole. Every other value is carried forward unchanged. Owner decision IN-064 option 1, 2026-11-06. |